What Is Thymosin Alpha-1?
Thymosin alpha-1 is a 28-amino-acid peptide produced naturally when a larger protein called prothymosin alpha is processed inside cells. A synthetic form, known as thymalfasin, has been developed as a medicine in some countries for selected infectious and immune-related conditions.
It is often described online as an “immune booster”. That phrase is too vague. Immune activity can be too weak, too strong or directed at the wrong target. Published results differ by disease, background treatment and trial quality. A large 2025 sepsis trial found no reduction in 28-day mortality.
What does thymosin alpha-1 mean?
Thymosins were first named because researchers isolated a mixture of small proteins and peptides from the thymus gland. The thymus is an organ behind the breastbone where T lymphocytes mature. T lymphocytes, or T cells, are white blood cells involved in recognising infected or abnormal cells and coordinating immune responses.
The early thymic preparation was called thymosin fraction 5. Researchers later separated and characterised individual components. Thymosin alpha-1 was the first peptide identified from the alpha group.
The pharmaceutical name thymalfasin refers to synthetic thymosin alpha-1. Zadaxin is a brand name used in some markets. A named medicine made under a national approval is not interchangeable with an unapproved vial sold as a research peptide.
What is thymosin alpha-1 made from?
Thymosin alpha-1 contains 28 amino acids. Its first amino acid is acetylated, meaning a small acetyl chemical group is attached to the beginning of the chain. This N-terminal acetylation matches the naturally occurring form and can affect stability and molecular recognition.
In the body, thymosin alpha-1 is produced from prothymosin alpha, a larger acidic protein found in many cell types. It is therefore not simply a hormone secreted only by the thymus.
The 28-amino-acid sequence is:
`Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn`
The sequence is included to define the molecule, not as manufacturing or administration guidance.
When was thymosin alpha-1 first documented?
Research on thymic extracts expanded in the 1960s and 1970s. Allan Goldstein and colleagues at George Washington University separated thymosin fraction 5 into individual components. Thymosin alpha-1 was isolated and characterised in the 1970s, with its amino-acid sequence reported in 1977.
Synthetic production allowed researchers to test one defined peptide rather than a mixture. Clinical research expanded during the 1980s and 1990s, particularly in chronic viral hepatitis and cancer.
| Period | Development |
|---|---|
| 1960s | Thymic extracts were investigated for immune-related activity |
| 1970s | Thymosin fraction 5 was separated and thymosin alpha-1 was isolated and sequenced |
| 1980s and 1990s | Synthetic thymalfasin entered trials in chronic viral hepatitis and cancer settings |
| 1999 | A multicentre Phase 3 hepatitis B trial was published |
| 2000s and 2010s | Studies expanded into sepsis, vaccines and other infections |
| 2020 onwards | COVID-19 studies produced mainly observational and mixed results |
| 2025 | The large TESTS Phase 3 trial found no 28-day mortality benefit in sepsis |
How is thymosin alpha-1 synthesised and manufactured?
Pharmaceutical thymalfasin can be made by solid-phase peptide synthesis. Protected amino acids are joined one by one on a resin. Because the chain contains 28 amino acids and several acidic or reactive side groups, each step must be controlled to limit deletion sequences and unwanted chemical changes.
After assembly, the peptide is separated from the resin, protective groups are removed and the N-terminal acetyl group is present in the required form. Preparative liquid chromatography separates the target peptide from incomplete chains, altered amino acids and processing residues.
Mass spectrometry and peptide mapping can check identity. Peptide mapping breaks the chain into fragments and compares the pattern with the expected sequence. Analytical chromatography estimates purity. A medicinal product also requires validated control of strength, sterility, endotoxin, aggregates, particles and stability.
Raw materials include protected versions of the 28 amino acids, resin, coupling reagents, solvents, acids and bases. Synthetic manufacture avoids extraction from animal thymus, but it does not remove the need for careful impurity and immune-risk assessment.
What does thymosin alpha-1 appear to do?
Laboratory studies report effects on innate and adaptive immunity. Innate immunity is the body's rapid, broad response to infection and damage. Adaptive immunity develops more specific responses through T cells and antibody-producing B cells.
Thymosin alpha-1 has been studied in relation to dendritic cells, T cells, natural killer cells and pattern-recognition receptors. Dendritic cells collect and present pieces of microbes or abnormal cells to T cells. Natural killer cells can destroy some infected or abnormal cells without the same type of prior recognition used by T cells.
Pattern-recognition receptors, including toll-like receptors, detect molecular features associated with microbes or cell damage. Changes in these pathways may alter cytokines, the signalling proteins immune cells use to communicate.
These mechanisms do not mean that thymosin alpha-1 strengthens every immune response. Depending on the context, it may increase some signals and regulate others. Clinical outcomes must be tested for each disease.
Why is “immune booster” an inadequate description?
The immune system is a network, not a single dial. Stronger inflammation can help clear an infection in one setting and damage organs in another. Autoimmune disease occurs when immune responses attack the body's own tissues.
A useful immunomodulator changes immune activity in a way that improves a defined outcome. Immunomodulator means a substance that alters immune responses. A higher T-cell count or changed cytokine level is not enough unless patients recover better, relapse less often or experience another meaningful benefit.
What did chronic hepatitis B studies find?
Hepatitis B is a viral infection of the liver. Chronic infection can lead to cirrhosis, liver failure and liver cancer. Viral DNA in blood and alanine aminotransferase, shortened to ALT, were common outcomes in older trials. ALT is an enzyme released when liver cells are injured.
Small early studies produced encouraging signals. A 1999 multicentre Phase 3 trial randomly assigned 98 people with chronic hepatitis B to thymosin alpha-1 or placebo. Phase 3 is the later stage of clinical development intended to confirm benefit and safety in a larger population. Double-blind means neither participants nor investigators knew the assignment during the trial.
The trial did not show a significant difference in its main sustained-response outcome at the initial time point, although later follow-up suggested delayed responses in some participants. This pattern led to interest but also uncertainty about the size and reliability of benefit.
A separate Japanese study randomised 316 participants to two thymosin alpha-1 exposure levels for 24 weeks. It compared levels rather than including an untreated placebo group. The study reported virological and biochemical outcomes but did not establish the peptide as a universal standard of care.
Modern hepatitis B treatment commonly uses potent oral antiviral medicines that directly suppress viral replication. Older thymalfasin results must be considered against current standards, not only against the treatment options available in the 1990s.
Study design, not dosing guidance
The hepatitis studies used defined thymalfasin products, subcutaneous administration and schedules set in trial protocols. Subcutaneous means into the fatty tissue beneath the skin. Published exposure levels are part of the historical study design. They are not instructions for using a compounded product.
The trials involved people with confirmed chronic viral infection, laboratory monitoring and defined follow-up. They cannot support general “immune maintenance” in healthy people.
What did hepatitis C research find?
Hepatitis C is a different virus. Older studies examined thymosin alpha-1 alone or with interferon. Interferon is an immune signalling protein that was formerly a central hepatitis C treatment but caused substantial adverse effects.
Results varied, and direct-acting antiviral medicines have since transformed care. Modern oral treatments can cure most hepatitis C infections. An older response in an interferon-era study does not justify replacing current antiviral treatment.
What did the TESTS sepsis trial find?
Sepsis is life-threatening organ dysfunction caused by the body's dysregulated response to infection. It is not simply an infection in the blood. Treatment requires rapid recognition, antimicrobial treatment, support for failing organs and control of the infection source.
The TESTS trial was a multicentre, double-blind, randomised, placebo-controlled Phase 3 study in China. It enrolled 1,106 adults with sepsis. The modified intention-to-treat analysis included 1,089 participants: 542 assigned to thymosin alpha-1 and 547 to placebo. Modified intention-to-treat means participants are analysed broadly according to their assigned group, with limited predefined exclusions.
At 28 days, 127 participants in the thymosin alpha-1 group had died, compared with 132 in the placebo group. These were 23.4% and 24.1%. The hazard ratio was 0.99 with a 95% confidence interval from 0.77 to 1.27.
A hazard ratio of 1 means no difference in the rate of the event between groups. A confidence interval describes the range compatible with the data under the statistical model. Because this interval crossed 1 and included possible benefit and harm, the trial found no clear mortality reduction. Secondary and safety outcomes also did not differ significantly.
This large negative trial carries more weight than smaller or uncontrolled reports suggesting benefit. It does not prove that the peptide has no biological effect. It shows that the tested regimen did not improve the main clinical outcome in this population.
Study design, not dosing guidance
TESTS used a specified hospital trial product alongside standard sepsis treatment for seven days. The study levels and schedule are relevant to interpreting the negative result, but they are not personal guidance. Sepsis is a medical emergency and cannot be treated through a research-peptide protocol.
What did COVID-19 studies find?
During the COVID-19 pandemic, thymosin alpha-1 was studied because severe illness can involve both damaging inflammation and impaired immune responses. Many reports were observational. In an observational study, clinicians do not randomly assign treatment, so people who receive a medicine may differ from those who do not.
Some studies reported lower mortality or improved immune measurements. Other analyses found no clear mortality benefit after accounting for differences between groups. Confounding is the influence of another factor, such as age or illness severity, that is linked to both treatment choice and outcome.
No evidence supports presenting thymosin alpha-1 as a routine COVID-19 prevention or treatment outside applicable national guidance. Vaccination, antiviral medicines and hospital care have separate evidence bases.
Has thymosin alpha-1 been studied in cancer?
Trials have examined thymosin alpha-1 alongside chemotherapy, immunotherapy or other cancer treatment. The aim was usually to improve immune function, reduce infection or support treatment response.
Results differ by cancer type and study design. A study of thymosin alpha-1 as an additional treatment does not show that it treats cancer by itself. Cancer survival claims require large controlled trials, defined tumour types and follow-up long enough to assess recurrence and harm.
People receiving cancer treatment should not use an immune-modifying product without their oncology team. Immune effects can interact with cancer immunotherapies, transplantation and autoimmune complications.
Does thymosin alpha-1 improve vaccine responses?
Some older studies examined thymosin alpha-1 as an adjuvant to influenza or hepatitis vaccination, particularly in people expected to have weaker responses. An adjuvant is something added or given with a vaccine to improve the immune response.
Small changes in antibody titres were reported in some populations. An antibody titre is a laboratory measure of antibody concentration. It is a surrogate outcome, meaning an indirect measure that may or may not predict clinical protection.
The evidence does not support routine use as a general vaccine booster. Vaccine schedules and licensed formulations should be evaluated on their own evidence.
What are the known and uncertain safety issues?
Trials of regulated thymalfasin products often report injection-site discomfort, redness, fatigue, headache or fever-like symptoms. Many studies describe acceptable short-term tolerability.
That does not establish safety for every population, route or compounded product. People with autoimmune disease, organ transplantation or treatment that deliberately suppresses or redirects immunity require particular caution because changing immune activity may be harmful.
The FDA identifies possible significant immunogenicity risk for certain compounded routes and complexities involving peptide impurities and active-ingredient characterisation. The agency states that the available safety information is inadequate to understand the full extent of risk.
Manufacturing matters. An aggregate is a cluster of peptide molecules. Aggregation and altered sequences can increase immune recognition. Sterility and endotoxin control are also essential for injectable products.
Is thymosin alpha-1 approved?
Approval varies by country and indication. The FDA's 2024 review states that thymosin alpha-1 is not approved in the United States, Japan or Europe except Italy. It has been marketed as thymalfasin in other national markets, with authorised uses that may include chronic hepatitis or immune-related indications.
An orphan drug designation in the United States is not approval. Orphan designation provides incentives to study a treatment for a rare condition. It does not mean the FDA has concluded that the medicine is safe and effective.
Compounding is also not approval. In December 2024, an FDA advisory committee discussed thymosin alpha-1 bulk substances for possible inclusion on the section 503A bulks list. The committee process does not create an approved medicine.
What benefits are claimed, and what does the evidence support?
| Claim | What the evidence supports |
|---|---|
| Boosts immunity in healthy people | No established general indication |
| Treats chronic hepatitis B | Mixed older trials; approval in some countries; current treatment context differs |
| Treats hepatitis C | Older interferon-era research; not a substitute for curative direct-acting antivirals |
| Reduces sepsis deaths | Not supported by the 1,106-participant TESTS Phase 3 trial |
| Treats COVID-19 | Observational and mixed evidence; no FDA-approved use |
| Improves cancer treatment | Condition-specific adjunct research; no general anticancer effect established |
| Improves vaccine response | Limited population-specific studies; no routine general use established |
How does thymosin alpha-1 differ from TB-500?
They are different molecules with different research histories. Thymosin alpha-1 is a 28-amino-acid product derived from prothymosin alpha and studied mainly in immune-related conditions. TB-500 is generally identified as a seven-amino-acid fragment related to thymosin beta-4 and is promoted for tissue repair.
The word thymosin reflects their history, not interchangeable activity.
What research would improve the evidence?
Future studies should focus on a specific disease, current standard treatment and an outcome that matters to patients. They should use a defined product, adequate randomisation, masking where possible and transparent adverse-event reporting.
Positive biomarker or subgroup findings should be confirmed in a new trial. A subgroup is a smaller set of participants selected by a feature such as age or immune status. Results found after looking through many subgroups can occur by chance.
How should different thymosin alpha-1 products be compared?
Evidence belongs to the product that was tested. A nationally authorised thymalfasin medicine has a defined manufacturer, sequence, formulation and quality system. A compounded preparation may use a different active-ingredient source, salt form, concentration and container.
The active sequence can be nominally the same while aggregation and impurities differ. Peptide-related impurities include missing amino acids, altered side chains, oxidation and incorrectly acetylated forms. These can reduce activity or alter immune recognition.
A study of Zadaxin in a country where it is approved therefore does not validate every product sold as thymosin alpha-1. Approval also applies to specified indications, not to general wellness or “immune optimisation”.
How do clinical outcomes differ from immune biomarkers?
Immune studies may count lymphocyte subsets, measure cytokines or test how cells respond outside the body. These biomarkers can help show that a peptide has biological activity.
For hepatitis, the outcomes may include viral DNA, liver enzymes, loss of viral antigens and liver damage. For sepsis, survival and organ support matter more than a change in one cytokine. For vaccination, actual protection from infection is more meaningful than an antibody change alone.
A biomarker can be misleading if it improves without helping the patient or if a treatment causes harm through another pathway. This is why the TESTS mortality result is more decisive for sepsis than a favourable laboratory immune signal.
Why do older hepatitis results need modern context?
Hepatitis B trial terminology can be difficult. HBeAg is a viral protein associated with active replication in many infections. Seroconversion means losing that antigen and developing a corresponding antibody. HBV DNA measures viral genetic material in blood.
ALT normalisation suggests less liver-cell injury, but ALT can fluctuate. A sustained virological response after treatment is more convincing than a single low reading.
Current oral nucleoside or nucleotide analogues can suppress hepatitis B replication effectively for many patients. Treatment decisions depend on viral levels, liver inflammation, fibrosis, age and cancer risk. A peptide result from the 1990s cannot be judged without that change in standard care.
For hepatitis C, direct-acting antivirals now cure most treated infections. Interferon-era combination research has little relevance to choosing current therapy.
Why did smaller sepsis studies look more favourable?
Earlier sepsis studies varied in diagnosis, severity, background care and whether thymosin alpha-1 was combined with other agents. Small samples can produce unstable estimates, and studies with positive results are more likely to be published.
Some meta-analyses combined trials that were not truly comparable. A meta-analysis pools results statistically, but the answer is only as reliable as the included studies. Bias in small trials does not disappear when their numbers are combined.
TESTS reduced several of these problems through randomisation, placebo control, blinding and a much larger sample. Its hazard ratio close to 1 indicated that the observed death rates were essentially alike under the tested conditions.
What does a confidence interval add to the result?
The TESTS hazard ratio was 0.99 and the 95% confidence interval ran from 0.77 to 1.27. The point estimate is the single best estimate from the data. The interval shows statistical uncertainty.
Because the interval included 1, the trial could not rule out no difference. It also included some possible benefit and possible harm, but not the large clear reduction expected from stronger earlier claims. The appropriate conclusion is no clear evidence of reduced 28-day mortality, not proof that the true effect is exactly zero.
What is known about long-term safety?
Most thymalfasin trials were designed around a specific illness and treatment period. They provide more human safety information than exists for many research peptides, but they do not answer every long-term question.
Immune effects may differ in autoimmune disease, after organ transplantation or alongside checkpoint-inhibitor cancer therapy. Checkpoint inhibitors are medicines that remove brakes from immune cells so they can attack tumours. Adding another immune-modifying signal could have unpredictable effects.
Rare immune reactions require large exposure numbers to detect. Product surveillance in one country may not transfer to an unregulated product elsewhere.
What would a useful new trial examine?
A new study should select people using a biological reason supported by prior data, not a broad label such as “low immunity”. It should define current standard treatment and ask whether thymalfasin adds a meaningful benefit.
The product, route and administration period should be fixed before the trial. Outcomes and subgroups should be registered in advance. Independent replication would be needed before a result became routine care.
For an infection, the trial should report recovery, hospital or intensive-care time, organ support, recurrence and mortality where appropriate. Laboratory immune changes would remain secondary unless validated as predictors of benefit.
Frequently asked questions
Is thymosin alpha-1 a peptide?
Yes. It is an acetylated chain of 28 amino acids.
Is thymosin alpha-1 made by the thymus?
It was first isolated from a thymus-derived preparation, but the natural peptide is produced from prothymosin alpha in several cell types.
Is thymosin alpha-1 an immune booster?
That phrase oversimplifies its biology. It is an immunomodulator studied in defined diseases, with results that vary by setting.
Did thymosin alpha-1 reduce deaths from sepsis?
No clear reduction was found in the large 2025 TESTS Phase 3 trial.
Is thymosin alpha-1 FDA approved?
No. It is not FDA approved. Approval varies in other countries, and the FDA reports approval in Italy but not elsewhere in Europe.
Is thymalfasin the same molecule?
Thymalfasin is the pharmaceutical name for synthetic thymosin alpha-1.
Does approval in one country validate every online product?
No. Approval applies to a particular product, manufacturer, indication and national decision.
Are trial administration levels personal guidance?
No. They document research conditions and do not provide instructions for unapproved products.
Sources
Research reviewed through September 2026.